2015年肿瘤治疗资料集中贴

老马 · 发表于 2015-7-2 16:45:22

三代药联合Cmet抑制剂

Rociletinib联合克药.pdf (786.14 KB, 下载次数: 137)

AZD9291联合AZD6094.pdf (294.88 KB, 下载次数: 143)

老马 · 发表于 2015-7-8 11:22:25

肝癌免疫治疗：靶向PD-1的惊人疗效
发表于 2015-06-1
2
在免疫治疗领域，PD-1/PD-L1和CTLA-4两个靶点可谓红得发紫。前一篇ASCO 2015摘要回顾中已经提及了靶向CTLA-4的初步结果，在另一篇口头报道中，报道了nivolumab（BMS公司，靶点为PD-1）的初步临床试验结果。这是一个1/2期临床试验，共有47名晚期肝癌患者入组了这项研究。这些患者多接受过其他抗肿瘤治疗，75%的患者接受过全身治疗，其中多数为索拉非尼治疗。

以索拉非尼的数据作为历史对照，在可评估客观缓解率的42个病例中，19%的患者获得了部分缓解，其中2例完全缓解。而索拉非尼的客观缓解率只有2%。48%的患者疾病稳定，其中最长者持续了17个月。一年生存率达到了62%，而索拉非尼的一年生存率只有30%。

此外，作者没有报道血清乙肝/丙肝病毒的缓解情况。

南加州大学的Anthony B. El-Khoueiry报道了上述结果。挺吓人的结果。
http://www.whyes.org/

鱼珊珊 · 发表于 2015-7-8 13:45:36

感谢老马和二师兄，虽然英文看不懂，但还好认识中文

老马 · 发表于 2015-8-5 21:11:24

NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor.
Abstract
The clinical efficacy of EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations is limited by the emergence of acquired resistance, mostly ascribed to the secondary EGFR-T790M mutation. Selective EGFR-T790M inhibitors have been proposed as a new, extremely relevant therapeutic approach. Here, we demonstrate that the novel irreversible EGFR-TKI CNX-2006, a structural analog of CO-1686, currently tested in a phase-1/2 trial, is active against in vitro and in vivo NSCLC models expressing mutant EGFR, with minimal effect on the wild-type receptor. By integration of genetic and functional analyses in isogenic cell pairs we provide evidence of the crucial role played by NF-κB1 in driving CNX-2006 acquired resistance and show that NF-κB activation may replace the oncogenic EGFR signaling in NSCLC when effective and persistent inhibition of the target is achieved in the presence of the T790M mutation. In this context, we demonstrate that the sole, either genetic or pharmacologic, inhibition of NF-κB is sufficient to reduce the viability of cells that adapted to EGFR-TKIs. Overall, our findings support the rational inhibition of members of the NF-κB pathway as a promising therapeutic option for patients who progress after treatment with novel mutant-selective EGFR-TKIs.
http://www.ncbi.nlm.nih.gov/pubmed/26015408

Bwjwdm · 发表于 2015-8-8 19:08:02

AACR_Abstract#CT138: 看今年AACR、ASCO的架势，纯粹是癌症免疫疗法吹牛逼大会，在一堆的PD1、CAR-T中，我终于找到一个还不错的另类，mTORC1/2抑制剂AZD2014联合紫杉醇对卵巢癌和非小细胞肺癌效果不错，应答率分别是3/7、2/5，患者之前都已经折腾好多遍了，包括紫杉醇类似的多西他赛。
二师兄，最近我们需要用到白蛋白紫杉醇化疗肺腺癌，关于这个2014的药哪里能买到？副作用有哪些？请赐教！急用，父脑转多发转移！